NL-OMON41521已完成不适用
The Generation R Study, Phase 3 - Focus at 9 - The Generation R Study, Phase 3 - Focus at 9
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 29,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 99（—）
入选标准
- •Pariticipation in Generation R Phase 3
- •Consent for participation in Generation R Phase 3
排除标准
- •Temporary or fully withdrawn from participating in the Generation R Study
- •Death of the child
研究者
相似试验
已完成
不适用
Generation R StudyThe study focuses on six primary research areas: (1) maternal health, (2) growth and physical development, (3) behaviour and cognitive development, (4) asthma and allergy, (5) diseases in childhood and (6) health care.NL-OMON24677Erasmus MC, University Medical Center Rotterdam9,778
进行中（未招募）
不适用
Estudio multicéntrico de fase III para investigar la eficacia y la seguridad del tratamiento abierto de 3 meses con PGL4001, seguido de un periodo aleatorizado, doble ciego y controlado con placebo de 10 días con progestina en pacientes con miomas y sangrado uterino abundante.A Phase III, multicentre, clinical study investigating the efficacy and safety of 3-months open-label treatment with PGL4001, followed by a randomised, double-blind placebo controlled period of 10 days treatment with progestin, in subjects with myomas and heavy uterine bleeding. - PEARL III: PGL4001 Efficacy Assessment in Reduction of symptoms due to uterine LeiomyomataEUCTR2010-018999-25-ESPregLem S.A.200
进行中（未招募）
1 期
Evaluación de masitinib en esclerosis múltiplePacientes con esclerosis múltiple primaria progresiva o secundaria progresiva sin recidivaMedDRA version: 14.0 Level: PT Classification code 10063401 Term: Primary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0 Level: PT Classification code 10063400 Term: Secondary progressive multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2010-021219-17-ESAB Science450
招募中
不适用
Generation R Next intervention studyNL-OMON53844Erasmus MC, Universitair Medisch Centrum Rotterdam1,750
进行中（未招募）
不适用
Estudio fase III, multicéntrico, simple ciego, randomizado, controlado con placebo, para evaluar la eficacia y seguridad de células madre expandidas derivadas de tejido adiposo autólogo (eASCs) (CX-401) para el tratamiento de la fístula perianal compleja en la enfermedad perianal de Crohn. FATT II: Fistula Advanced Therapy Trial (II).Randomized, single-blind, placebo-controlled multicenter phase III study to assess the efficacy and safety of expanded autologous adipose-derived stem cells (eASCs) (CX-401), for treatment of complex perianal fistulas in Crohn?s disease. FATT 2: Fistula Advanced Therapy Trial (II) - FATT IIFístula perianal compleja en pacientes con enfermedad de Crohn.Complex perianal fistula in perianal Crohn´s diseaseMedDRA version: 9Level: LLTClassification code 10002156Term: Anal fistulaEUCTR2008-004286-25-ESCELLERIX S.A.196